FLGT
Fulgent Genetics Inc

5,732
Mkt Cap
$695.74M
Volume
84,341.00
52W High
$24.64
52W Low
$14.57
PE Ratio
-13.62
FLGT Fundamentals
Price
$22.66
Prev Close
$22.73
Open
$22.93
50D MA
$22.46
Beta
0.86
Avg. Volume
234,319.57
EPS (Annual)
-$1.41
P/B
0.62
Rev/Employee
$215,894.90
Loading...
Loading...
News
all
press releases
Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength?
Schrodinger (SDGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·9d ago
News Placeholder
More News
News Placeholder
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·14d ago
News Placeholder
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·9mo ago
News Placeholder
Fulgent Reports Third Quarter 2024 Financial Results
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·1y ago
News Placeholder
Uncovering Potential: Fulgent Genetics's Earnings Preview
read more...
Benzinga·1y ago
News Placeholder
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. (NASDAQ:FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·1y ago
News Placeholder
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·1y ago
News Placeholder
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·1y ago
News Placeholder
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·1y ago

Latest FLGT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.